Intelligence for decisions, partnerships and market expansion.
Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.
Viemed Healthcare, a U.S. provider of home medical equipment and post-acute healthcare services, announced it will present at the 20th Annual LD Micro Main Event on October 20, 202...
Cigna has launched its "Lead to One" vision, aiming for 10-14% adjusted EPS growth through 2030 and reaffirming 2026 financial guidance. The strategy focuses on integrating Cigna H...
A Discounted Cash Flow (DCF) analysis for HCA Healthcare Inc (HCA) suggests the stock is undervalued, with an intrinsic value of $740.05 against a current price of $434.92. Both ea...
This article is a security check and does not contain substantive content. It is likely a placeholder or an error in content retrieval.
Wells Fargo has maintained its Buy rating for Voyager Therapeutics (VYGR) stock and set a price target of USD 10.00, significantly above its current Nasdaq price of USD 2.46. This...
Viemed Healthcare, Inc. announced its participation in the 20th Annual LD Micro Main Event, scheduled for October 19-21, 2026, in Los Angeles, California. The company will present...
This article compares Johnson & Johnson (JNJ) and Procter & Gamble (PG) as potential long-term dividend investments, both being Dividend Kings with similar valuations. The author c...
Viking Therapeutics has initiated the second part of a study investigating oral and subcutaneous VK2735, a dual GLP-1/GIP receptor agonist, for maintaining weight loss in obese adu...
Viking Therapeutics has initiated Part 2 of an exploratory maintenance dosing study for its dual GLP-1/GIP receptor agonist, VK2735. This trial will enroll 195 adults with obesity...
Viking Therapeutics has initiated the second part of its VK2735 oral maintenance dosing clinical trial for obesity, exploring various oral and subcutaneous regimens to maintain ini...